AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19105351 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment for flat warts (control group).
Number of subjects: 0
Study 16632814 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron (0.1 mg/kg)
Number of subjects: 75
Study 16632814 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 16632814 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine (1.5 microg/kg)
Number of subjects: 75
Study 12741308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP)
Number of subjects: 21
Study 12741308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 21
Study 10843152 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 299
Study 10843152 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin 200 IU
Number of subjects: 299
Study 8983912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 0
Study 8983912 — intervention group
Group type: EXPERIMENTAL
Intervention: Carebastine
Number of subjects: 0
Study 2205961 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet), taken thrice daily for eight weeks
Number of subjects: 48
Study 2205961 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken thrice daily for eight weeks
Number of subjects: 48
Study 2205961 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet)
Number of subjects: 48
Study 2205961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 626821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hepatic artery ligation and portal vein perfusion
Number of subjects: 0
Study 626821 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery ligation and perfusion
Number of subjects: 0
Study 626821 — intervention group
Group type: COMPARATOR
Intervention: Portal vein perfusion alone
Number of subjects: 0
Study 31831201 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM-derived personalised feedback
Number of subjects: 50
Study 31831201 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 50
Study 31399448 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) infusion (2500 mg/25 mL over 10 min, followed by the same doses at 24, 48, and 72 hours)
Number of subjects: 50
Study 31399448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28122364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (S)
Number of subjects: 0
Study 28122364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose + Maltodextrin (S+M)
Number of subjects: 0
Study 28122364 — intervention group
Group type: COMPARATOR
Intervention: Deionized Distilled Water (DDW)
Number of subjects: 0
Study 28122364 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (M)
Number of subjects: 0
Study 25348807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of both wound edges with 20 ml of 0.75% ropivacaine
Number of subjects: 40
Study 25348807 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infiltration (placebo)
Number of subjects: 40
Study 23480028 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 μg/kg) intravenously alone
Number of subjects: 16
Study 23480028 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 μg/kg) intravenously with rifampicin (600 mg single oral dose)
Number of subjects: 16
Study 22153009 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban + aspirin and clopidogrel
Number of subjects: 325
Study 19786678 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEIs)
Number of subjects: 1094
Study 19786678 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blocker (CCB)
Number of subjects: 1094
Study 19786678 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker (BB)
Number of subjects: 1094
Study 19786678 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 1094
Study 19786678 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR between 31 and 40 mL/min/1.73 m²
Number of subjects: 1094
Study 19786678 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR < 30 mL/min/1.73 m²
Number of subjects: 1094
Study 19786678 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR 41 to 50 mL/min/1.73 m²
Number of subjects: 1094
Study 16941613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal spray
Number of subjects: 17
Study 16941613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal spray and hydroxyurea capsule
Number of subjects: 17
Study 16941613 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 17
Study 16941613 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea capsule and placebo nasal spray
Number of subjects: 17
Study 16510377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg once daily
Number of subjects: 130
Study 16510377 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 130
Study 14753137 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with propofol and remifentanil (2 and 0.2‐0.4 microgram/Kg/h)
Number of subjects: 120
Study 14753137 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with lidocaine
Number of subjects: 120
Study 14753137 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with 1.5% prilocaine
Number of subjects: 120
Study 14753137 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study 9476719 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI‐based linear measurements of the hippocampus and parahippocampal gyrus complex
Number of subjects: 87
Study 9476719 — intervention group
Group type: EXPERIMENTAL
Intervention: Left height of the HPC at the level of the mammillary bodies
Number of subjects: 87
Study 7709462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS, 10‐20 mg o.d.)
Number of subjects: 8
Study 7709462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (NIT, 10‐20 mg b.i.d.)
Number of subjects: 8
Study 7709462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2540654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 266
Study 2540654 — intervention group
Group type: COMPARATOR
Intervention: Barrier contraception
Number of subjects: 266
Study 350736 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP (maprotiline)
Number of subjects: 86
Study 350736 — intervention group
Group type: COMPARATOR
Intervention: AMT (amitriptyline)
Number of subjects: 86
Study 30056216 — intervention group
Group type: EXPERIMENTAL
Intervention: acebilustat 50 mg
Number of subjects: 200
Study 30056216 — intervention group
Group type: EXPERIMENTAL
Intervention: acebilustat 100 mg
Number of subjects: 200
Study 30056216 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study 27362705 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral medication (Group-I, control)
Number of subjects: 297
Study 27362705 — intervention group
Group type: EXPERIMENTAL
Intervention: Abundant water intake (Group-II)
Number of subjects: 297
Study 27362705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic ventilation tubes (Group-III)
Number of subjects: 297
Study 27362705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping in darkness (Group-IV)
Number of subjects: 297
Study 25740742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasointestinal tube (NIT) feeding
Number of subjects: 70
Study 25740742 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube (NGT) feeding
Number of subjects: 70
Study 23756915 — intervention group
Group type: COMPARATOR
Intervention: T‐piece resuscitator alone
Number of subjects: 19
Study 23756915 — intervention group
Group type: EXPERIMENTAL
Intervention: PediCap CO2 detector
Number of subjects: 19
Study 23756915 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoStat CO2 detector
Number of subjects: 19
Study 20966373 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive collaborative treatment (CSCT)
Number of subjects: 100
Study 20966373 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 100
Study 20966373 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 19132271 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation I: W(kg) = 0.5030 (AC) + 0.5634 (AbC) + 1.3180 (CC) + 0.0339 (SSSF) - 43.1560
Number of subjects: 100
Study 19132271 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation II: W(kg) = 0.4808 (AC) + 0.5646 (AbC) + 1.3160 (CC) - 42.2450
Number of subjects: 100
Study 19132271 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation IV
Number of subjects: 100
Study 19132271 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation V
Number of subjects: 100
Study 19132271 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation III: W(kg) = 0.5759 (AC) + 0.5263 (AbC) + 1.2452 (CC) - 4.8689 (S) - 32.9241
Number of subjects: 100
Study 19132271 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation V: VH(m) = 63.525 - 3.237(S) - 0.06904(A) + 1.293(HS)
Number of subjects: 100
Study 15845683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg daily)
Number of subjects: 9
Study 15845683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg daily) and Erythromycin (1500 mg)
Number of subjects: 9
Study 15845683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12960646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine (Havrix), 720 Elisa units per 0.5 ml dose, administered at months 0 and 6
Number of subjects: 89
Study 12960646 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls, 55 participants (mean age: 4.8 ± 2.7 years)
Number of subjects: 89
Study 10518370 — intervention group
Group type: EXPERIMENTAL
Intervention: Two estimators for expected quality adjusted survival
Number of subjects: 0
Study 10518370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample-based variance estimates
Number of subjects: 0
Study 10518370 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation procedures
Number of subjects: 0
Study 8808515 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 78
Study 8808515 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 78
Study 8808515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 1753043 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise condition
Number of subjects: 101
Study 1753043 — intervention group
Group type: COMPARATOR
Intervention: Non‐aerobic yoga
Number of subjects: 101
Study 1753043 — intervention group
Group type: COMPARATOR
Intervention: Wait list non‐exercise control group
Number of subjects: 101
Study 6970272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin prophylaxis (20 mg/kg once daily for four days)
Number of subjects: 39
Study 31884186 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0
Study 31884186 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 0
Study 31464176 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 100
Study 31464176 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 100
Study 31464176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BiV pacing and defibrillation (BiV-D) devices
Number of subjects: 100
Study 31464176 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker (BiV-P)
Number of subjects: 100
Study 28406936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise before task practice
Number of subjects: 29
Study 28406936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after task practice
Number of subjects: 29
Study 28406936 — intervention group
Group type: COMPARATOR
Intervention: Task practice only
Number of subjects: 29
Study 26505161 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual environment (LIVE site) with synchronous classes and peer support for self-management.
Number of subjects: 300
Study 26505161 — intervention group
Group type: COMPARATOR
Intervention: Traditional asynchronous Web format with the same informational and educational content.
Number of subjects: 300
Study 23318842 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interview
Number of subjects: 384
Study 23318842 — intervention group
Group type: COMPARATOR
Intervention: Usual interview
Number of subjects: 384
Study 22010250 — intervention group
Group type: EXPERIMENTAL
Intervention: PHL-NP122 (10^6 spores/g of feed)
Number of subjects: 10
Study 22010250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitarsone (0.019%)
Number of subjects: 10
Study 22010250 — intervention group
Group type: EXPERIMENTAL
Intervention: PHL-MM65 (10^6 spores/g of feed)
Number of subjects: 10
Study 22010250 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 22010250 — intervention group
Group type: EXPERIMENTAL
Intervention: PHL-NP122 and PHL-MM65
Number of subjects: 10
Study 22010250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitarsone
Number of subjects: 10
Study 22010250 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 10
Study 19321970 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparator (antidepressant)
Number of subjects: 90
Study 19321970 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week trials
Number of subjects: 90
Study 19321970 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week trials
Number of subjects: 90
Study 19321970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17446205 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin (40 g)
Number of subjects: 28
Study 17446205 — intervention group
Group type: COMPARATOR
Intervention: casein-derived control protein
Number of subjects: 28
Study 14736964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 60
Study 14736964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14736964 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 60
Study 10795721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (math task involving subtraction by threes)
Number of subjects: 26
Study 10795721 — intervention group
Group type: COMPARATOR
Intervention: Control task (balance only)
Number of subjects: 26
Study 10795721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (math task)
Number of subjects: 26
Study 9505387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid sorption
Number of subjects: 16
Study 8417039 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional program
Number of subjects: 20
Study 8417039 — intervention group
Group type: COMPARATOR
Intervention: Literature-based educational units
Number of subjects: 20
Study 3092656 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 50
Study 3092656 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms in the morning
Number of subjects: 50
Study 3092656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg three times daily and 400 mg at night
Number of subjects: 50
Study 3092656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times daily
Number of subjects: 50
Study 3092656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29628759 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7624
Number of subjects: 213
Study 29628759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 27435836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) intravenous infusion (0.24 to 0.6 μg/kg/h) for <24 hours postoperatively
Number of subjects: 505
Study 22716129 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer compression bandage system
Number of subjects: 103
Study 22716129 — intervention group
Group type: COMPARATOR
Intervention: Class 3 compression hosiery
Number of subjects: 103
Study 22716129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 103
Study 22446609 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD followed by 30 Gy of involved-field radiation therapy
Number of subjects: 98
Study 22446609 — intervention group
Group type: COMPARATOR
Intervention: Two cycles of ABVD followed by 20 Gy of involved-field radiation therapy
Number of subjects: 98
Study 22446609 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy of involved-field radiation therapy
Number of subjects: 98
Study 22446609 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy of involved-field radiation therapy
Number of subjects: 98
Study 20406769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 1131
Study 20406769 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 1131
Study 19552060 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 3 months
Number of subjects: 0
Study 19552060 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no antihypertensive therapy)
Number of subjects: 0
Study 15911668 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect percutaneous reduction and external fixation (n = 88)
Number of subjects: 179
Study 15911668 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (n = 91)
Number of subjects: 179
Study 15911668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study 12883138 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs) including clomipramine, fluvoxamine, fluoxetine, sertraline, and paroxetine
Number of subjects: 0
Study 12883138 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching, augmentation, or novel-agent strategies for patients who do not respond to SRIs
Number of subjects: 0
Study 12883138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic invasive techniques
Number of subjects: 0
Study 11021272 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment consisting of ACE inhibitors (91% of patients), ACE inhibitor dosage (52% of recommended dose), β‐blockers (42%), diuretics (70%), digitalis (63%)
Number of subjects: 512
Study 11021272 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted defibrillators (1.4% of patients)
Number of subjects: 512
Study 8750753 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent telephone contact during the first 3 months post-dispensing
Number of subjects: 55
Study 8750753 — intervention group
Group type: COMPARATOR
Intervention: No frequent telephone contact (Control)
Number of subjects: 55
Study 2336056 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A (sucrose and maltodextrin)
Number of subjects: 13
Study 2336056 — intervention group
Group type: COMPARATOR
Intervention: Solution B (glucose)
Number of subjects: 13
Study 6986133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 to 25 mg/day)
Number of subjects: 1
Study 6986133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 31199749 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2
Number of subjects: 72
Study 31199749 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal
Number of subjects: 72
Study 31199749 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 72
Study 31199749 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1
Number of subjects: 72
Study 31199749 — intervention group
Group type: COMPARATOR
Intervention: Conventional aging (6 months of water storage)
Number of subjects: 72
Study 31199749 — intervention group
Group type: COMPARATOR
Intervention: Accelerated aging (pH‐cycling method)
Number of subjects: 72
Study 31199749 — intervention group
Group type: COMPARATOR
Intervention: Negative control (immediate bond strength)
Number of subjects: 72
Study 30419850 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) grade 1
Number of subjects: 1403
Study 30419850 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) grade 2
Number of subjects: 1403
Study 30419850 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) grade ≥3
Number of subjects: 1403
Study 30419850 — intervention group
Group type: COMPARATOR
Intervention: Adenocarcinomas
Number of subjects: 1403
Study 30419850 — intervention group
Group type: COMPARATOR
Intervention: Squamous cell carcinomas
Number of subjects: 1403
Study 30419850 — intervention group
Group type: COMPARATOR
Intervention: Small cell cancers
Number of subjects: 1403
Study 26848937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mama kits (US$4 incentive)
Number of subjects: 30
Study 24726639 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 44
Study 24726639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22924169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.30 mg/kg
Number of subjects: 120
Study 22924169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 120
Study 22924169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20332353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study 20332353 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study 20332353 — intervention group
Group type: COMPARATOR
Intervention: DSE (optimal care goals)
Number of subjects: 5145
Study 20332353 — intervention group
Group type: EXPERIMENTAL
Intervention: ILI (optimal care)
Number of subjects: 5145
Study 18039205 — intervention group
Group type: EXPERIMENTAL
Intervention: High MAP group (mean arterial pressure target during CPB was 80 mmHg)
Number of subjects: 412